<DOC>
	<DOCNO>NCT00728351</DOCNO>
	<brief_summary>The present study design evaluate efficacy safety fix combination therapy vildagliptin metformin ( 25/1000 mg bid ) patient type 2 diabetes inadequately control prior metformin monotherapy .</brief_summary>
	<brief_title>Efficacy Safety Fixed Combination Therapy Vildagliptin Metformin ( 25/1000 mg Bid ) Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy ( HbA1c 7.0-9.5 % )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>History T2DM treat Metformin FPG &gt; = 260 mg/dL ( 14.4mmol/L ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes , vildagliptin</keyword>
</DOC>